Acorda Therapeutics (ACOR) Research Coverage Started at Wedbush
Research analysts at Wedbush started coverage on shares of Acorda Therapeutics (NASDAQ:ACOR) in a research report issued to clients and investors on Wednesday, The Fly reports. The brokerage set a “neutral” rating on the biopharmaceutical company’s stock.
ACOR has been the topic of a number of other research reports. BidaskClub lowered Acorda Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, March 22nd. Zacks Investment Research upgraded Acorda Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, May 3rd. JPMorgan Chase & Co. reiterated a “hold” rating and issued a $18.00 target price on shares of Acorda Therapeutics in a research report on Tuesday, May 7th. ValuEngine upgraded Acorda Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 1st. Finally, HC Wainwright set a $33.00 target price on Acorda Therapeutics and gave the company a “buy” rating in a research report on Wednesday, January 23rd. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company. Acorda Therapeutics currently has a consensus rating of “Hold” and an average price target of $22.56.
Shares of ACOR traded up $0.04 during mid-day trading on Wednesday, hitting $10.97. 600,158 shares of the company traded hands, compared to its average volume of 873,844. Acorda Therapeutics has a 1-year low of $9.58 and a 1-year high of $36.35. The company has a quick ratio of 3.97, a current ratio of 4.30 and a debt-to-equity ratio of 0.66. The company has a market cap of $526.54 million, a P/E ratio of 6.03 and a beta of 1.34.
Institutional investors have recently added to or reduced their stakes in the business. Bank of Montreal Can boosted its position in Acorda Therapeutics by 100.8% in the 4th quarter. Bank of Montreal Can now owns 2,116 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 1,062 shares in the last quarter. Oppenheimer Asset Management Inc. purchased a new stake in Acorda Therapeutics in the 4th quarter worth approximately $44,000. Financial Gravity Wealth Inc. purchased a new stake in Acorda Therapeutics in the 1st quarter worth approximately $44,000. NumerixS Investment Technologies Inc purchased a new stake in Acorda Therapeutics in the 4th quarter worth approximately $77,000. Finally, Piedmont Investment Advisors Inc. purchased a new stake in Acorda Therapeutics in the 1st quarter worth approximately $134,000.
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe.
See Also: What is intrinsic value?
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.